Infectious Diseases Section, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.
Bonn University Hospital, Institute for Hygiene and Public Health, Bonn, Germany.
J Antimicrob Chemother. 2020 Dec 6;75(Suppl 2):ii2-ii19. doi: 10.1093/jac/dkaa425.
To systematically summarize the evidence on how to collect, analyse and report antimicrobial resistance (AMR) surveillance data to inform antimicrobial stewardship (AMS) teams providing guidance on empirical antibiotic treatment in healthcare settings.
The research group identified 10 key questions about the link between AMR surveillance and AMS using a checklist of 9 elements for good practice in health research priority settings and a modified 3D combined approach matrix, and conducted a systematic review of published original studies and guidelines on the link between AMR surveillance and AMS.
The questions identified focused on AMS team composition; minimum infrastructure requirements for AMR surveillance; organisms, samples and susceptibility patterns to report; data stratification strategies; reporting frequency; resistance thresholds to drive empirical therapy; surveillance in high-risk hospital units, long-term care, outpatient and veterinary settings; and surveillance data from other countries. Twenty guidelines and seven original studies on the implementation of AMR surveillance as part of an AMS programme were included in the literature review.
The evidence summarized in this review provides a useful basis for a more integrated process of developing procedures to report AMR surveillance data to drive AMS interventions. These procedures should be extended to settings outside the acute-care institutions, such as long-term care, outpatient and veterinary. Without proper AMR surveillance, implementation of AMS policies cannot contribute effectively to the fight against MDR pathogens and may even worsen the burden of adverse events from such interventions.
系统总结有关如何收集、分析和报告抗菌药物耐药性(AMR)监测数据的证据,为在医疗保健环境中提供经验性抗生素治疗指导的抗菌药物管理(AMS)团队提供信息。
研究小组使用健康研究优先领域的 9 项良好实践要素清单和改良的 3D 综合方法矩阵确定了 10 个有关 AMR 监测与 AMS 之间联系的关键问题,并对 AMR 监测与 AMS 之间联系的已发表原始研究和指南进行了系统评价。
确定的问题集中在 AMS 团队组成;AMR 监测的最低基础设施要求;报告的生物体、样本和药敏模式;数据分层策略;报告频率;驱动经验性治疗的耐药阈值;高风险医院单位、长期护理、门诊和兽医环境中的监测;以及来自其他国家的监测数据。对 AMR 监测作为 AMS 计划的一部分的实施的 20 项指南和 7 项原始研究被纳入文献综述。
本综述中总结的证据为更综合的过程提供了有用的基础,以便制定报告 AMR 监测数据以驱动 AMS 干预的程序。这些程序应扩展到急性护理机构以外的环境,如长期护理、门诊和兽医。如果没有适当的 AMR 监测,AMS 政策的实施就不能有效地对抗 MDR 病原体,甚至可能使此类干预措施的不良事件负担恶化。